Veterinary Medicine and Research2022-11-15T15:27:11-05:00

Veterinary Medicine and Research.

Address Reagent, Biomarker, and Therapeutic Gaps in Veterinary Medicine and Research.

As human and animal populations continue to grow worldwide, so do the demands in products that sustain and manage human and animal welfare. In the past few decades, there have been a number of important advances in the veterinary field; however, information gaps are still very much present due to the limited understanding of many species’ immune systems. This is largely due to the shortage of whole genome sequencing data and the lack of immunological reagents for many species.

Next generation protein sequencing (NGPS) allows for: direct access to the protein to fill in species-specific genetic data gaps; characterization of complex zoonotic bacterial, viral, prion antigens and their associated post-translational modifications; diagnostics development by identifying custom anti-drug and anti-hapten antibodies; and development of antibody therapeutics.

Webinar

Alpaca Antibody Showdown – Selecting Specific Monoclonal Antibodies by SPR

Nov 30, 11 am EST

Services for Veterinary Medicine and Research.

We support research and development efforts in the animal health industries. Contact Us to discover how we can help with your veterinary medicine and research application.

de novo mAb Sequencing

Sequence antibodies that bind to complex zoonotic protein targets (eg. prions) to easily develop diagnostic, purification and characterization tools.
Explore REmAb

Therapeutic mAb Development

Sequence and identify mAbs from the serum of companion and livestock animals for therapeutics development.

Explore REpAb

Epitope Mapping

Characterize prion protein structures under misfolding-promoting conditions, and other antigenic epitopes of interest.
Explore HDX-MS

ADA Reagent Development

Derive custom anti-drug antibody (ADA) control reagents from circulating pAbs without culling the producer animal for improved ADA assays.

Explore REpAb

Anti-Hapten Antibody Discovery

Identify anti-hapten antibodies from circulating pAbs for improved diagnostics of antimicrobials within our food supply chain.

Explore REpAb

Recombinant Expression

With the protein sequence in hand, recombinantly express mAbs to secure important immunoreagents.
Explore Antibody Expression

Application Publications.

Broadly Neutralizing Antibody Cocktails Targeting Nipah Virus and Hendra Virus Fusion Glycoproteins

Tags: , , , , , , |

Hendra virus (HeV) and Nipah virus (NiV) are types of Henipaviruses (HNVs) that originated in bats and can infect the human respiratory system with detrimental consequences. As enveloped, single-stranded RNA viruses, HeV and NiV use attachment (G) and fusion (F) glycoproteins on the envelope membrane to enter host cells. So far, there are no approved therapeutics or vaccines to combat the viruses in humans.

Sequencing and Recombinant Expression of Goat Antibodies from a Polyclonal Mixture

Tags: , , , , , |

Circulating in blood is a multitude of biologically important antibodies. These pools of polyclonal antibodies (pAb) are invaluable sources for drug discovery against various diseases, and for the development of robust immunoreagents for diagnostics, and research.

Next Generation Protein Sequencing in Veterinary Medicine and Industry

Tags: , , , , , , , , , , , , |

Since 2006, the One Health Initiative (OHI)’s goal has been to demonstrate the inextricable link between humans, animals, and the environment. Certainly, the current global pandemic is a great testament to the ties between climate change, humans, and animals that OHI has been working to highlight. The rise of other zoonotic diseases (e.g., Hendra, and Nipah viruses) not only directly affect humans through disease transmission but may also result in deep impacts to the food supply

“We’re focused on coupling cytokines with a highly engineered VHVL of an antibody. So by sequencing the antibodies with Rapid Novor we are able to pull out the CDR to graft them into our platform and test in vitro and in vivo.”

Pavel Khrimian – Co-founder and CBO, Deka Biosciences

Talk to Our Scientists.

We Have Sequenced 7000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.

Talk to Our Scientists.

We Have Sequenced 6000+ Antibodies and We Are Eager to Help You.

Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics

Talk to our scientists. We have sequenced over 6000 antibodies and we are eager to help you.